Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Imfinzi also recommended for patients with mismatch repair deficient disease
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Subscribe To Our Newsletter & Stay Updated
